Tech GIANT’s Plans to Revolutionize Crypto…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

Kathleen Goetz Biography and Net Worth

Director of Abrdn Life Sciences Investors

Trustee, HQH, HQL, THQ and THW (since 2021); Consultant (Since 2020); Novartis Pharmaceuticals: Vice President and Head of Sales (2017-2019), Executive Director of Strategic Account Management (2015-2016), Regional Sales Director - Neuroscience Business Unit (2012-2015), Marketing Brand Director - Reclast (2011), Ad Interim General Manager (2010), Managing Sales Director (2008-2010) and Integrated Markets, Strategic Planning (2007-2008).

What is Kathleen Goetz's net worth?: The estimated net worth of Kathleen Goetz is at least $14,839.20 as of April 9th, 2024. Ms. Goetz owns 1,080 shares of Abrdn Life Sciences Investors stock worth more than $14,839 as of May 8th. This net worth estimate does not reflect any other investments that Ms. Goetz may own. Learn More about Kathleen Goetz's net worth.
How do I contact Kathleen Goetz?: The corporate mailing address for Ms. Goetz and other Abrdn Life Sciences Investors executives is 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109. Abrdn Life Sciences Investors can also be reached via phone at (617) 772-8500 and via email at [email protected]. Learn More on Kathleen Goetz's contact information.
Has Kathleen Goetz been buying or selling shares of Abrdn Life Sciences Investors?: During the last ninety days, Kathleen Goetz has bought $5,328.00 in Abrdn Life Sciences Investors stock. Most recently, on Tuesday, April 9th, Kathleen Goetz bought 400 shares of Abrdn Life Sciences Investors stock. The stock was acquired at an average cost of $13.32 per share, with a total value of $5,328.00. Following the completion of the transaction, the director now directly owns 1,085 shares of the company's stock, valued at $14,452.20. Learn More on Kathleen Goetz's trading history.
Who are Abrdn Life Sciences Investors' active insiders?: Abrdn Life Sciences Investors' insider roster includes Kathleen Goetz (Director), and Daniel Omstead (President). Learn More on Abrdn Life Sciences Investors' active insiders.
Are insiders buying or selling shares of Abrdn Life Sciences Investors?: In the last year, Abrdn Life Sciences Investors insiders bought shares 11 times. They purchased a total of 301,649 shares worth more than $3,919,122.27. The most recent insider tranaction occured on May, 6th when Major Shareholder Saba Capital Management, L.P. bought 10,713 shares worth more than $145,911.06. Insiders at Abrdn Life Sciences Investors own 10.1% of the company. Learn More about insider trades at Abrdn Life Sciences Investors.
Information on this page was last updated on 5/6/2024.

Kathleen Goetz Insider Trading History at Abrdn Life Sciences Investors

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/9/2024	Buy	400	$13.32	$5,328.00	1,085
3/23/2022	Buy	92	$16.27	$1,496.84
1/26/2022	Buy	593	$17.54	$10,401.22

Kathleen Goetz Buying and Selling Activity at Abrdn Life Sciences Investors

Abrdn Life Sciences Investors Company Overview

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Today's Range

Now: $13.74

$13.69

$13.79

50 Day Range

MA: $13.40

$12.79

$13.93

2 Week Range

Now: $13.74

$11.34

$14.37

Volume

93,949 shs

Average Volume

108,034 shs

Market Capitalization

$375.79 million

P/E Ratio

N/A

Dividend Yield

9.79%

Beta

0.73